COMMUNIQUÉ DE PRESSE publié le 28/11/2023 à 12:40, il y a 2 années 3 mois The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 15/11/2023 à 12:45, il y a 2 années 4 mois NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
COMMUNIQUÉ DE PRESSE publié le 14/11/2023 à 12:45, il y a 2 années 4 mois Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
COMMUNIQUÉ DE PRESSE publié le 16/10/2023 à 12:45, il y a 2 années 5 mois NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
COMMUNIQUÉ DE PRESSE publié le 12/10/2023 à 12:45, il y a 2 années 5 mois NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
COMMUNIQUÉ DE PRESSE publié le 21/08/2023 à 12:45, il y a 2 années 6 mois The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 11/07/2023 à 12:45, il y a 2 années 8 mois Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 12:45, il y a 2 années 8 mois Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
COMMUNIQUÉ DE PRESSE publié le 29/06/2023 à 12:45, il y a 2 années 8 mois NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
COMMUNIQUÉ DE PRESSE publié le 31/05/2023 à 12:40, il y a 2 années 9 mois NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Publié le 20/03/2026 à 19:00, il y a 14 heures 43 minutes AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Publié le 20/03/2026 à 19:00, il y a 14 heures 43 minutes AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Publié le 20/03/2026 à 18:15, il y a 15 heures 28 minutes Publication of AXA’s 2025 Universal Registration Document
Publié le 20/03/2026 à 18:15, il y a 15 heures 28 minutes Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Publié le 20/03/2026 à 21:15, il y a 12 heures 28 minutes Earthwise Minerals Announces Private Placement
Publié le 20/03/2026 à 13:30, il y a 20 heures 13 minutes Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Publié le 20/03/2026 à 12:30, il y a 21 heures 13 minutes CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Publié le 20/03/2026 à 22:45, il y a 10 heures 58 minutes Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Publié le 20/03/2026 à 21:05, il y a 12 heures 38 minutes Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Publié le 20/03/2026 à 21:05, il y a 12 heures 38 minutes Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Publié le 20/03/2026 à 21:00, il y a 12 heures 43 minutes BRP Unveils the Winners of its 6th International Design Challenge
Publié le 20/03/2026 à 20:05, il y a 13 heures 38 minutes INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action
